Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754049 | 0.87 | ADORA2A (0.60) | CYP1A2CYP2D6MAPK1ADORA2AADORA2B | |
| SCHEMBL21539317 | 0.83 | CYP1A2 (0.51) | CYP1A2CYP2D6MAPK1ADORA2AADORA2B | |
| SCHEMBL21943154 | 0.81 | ADORA2A (0.64) | CYP1A2CYP2D6MAPK1ADORA2AADORA2B | |
| SCHEMBL22399739 | 0.81 | CYP1A2 (0.52) | CYP1A2CYP2D6MAPK1ADORA2AADORA2B | |
| SCHEMBL24205121 | 0.78 | ADORA2A (0.77) | CYP1A2ADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL18521145 | 0.78 | ADORA2A (0.77) | CYP1A2ADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL22399292 | 0.78 | ADORA2A (0.53) | CYP1A2ADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL6364457 | 0.77 | ADORA2A (0.61) | CYP1A2CYP2D6MAPK1ADORA2AADORA2B | |
| SCHEMBL24409387 | 0.77 | ADORA2A (0.51) | CYP1A2ADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL21539218 | 0.77 | ADORA2A (0.51) | CYP1A2ADORA2AADORA2BADORA1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | CYP1A2 1485/4885CYP2D6 2541/4885MAPK1 1162/4885 |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | CYP1A2 1468/4885CYP2D6 2515/4885MAPK1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.